TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Lagoda Investment Management L.P.

Lagoda Investment Management L.P. increased its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 16.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 73,860 shares of the company's stock after acquiring an additional 10,555 shares during the quarter. TransMedics Group makes up about 2.5% of Lagoda Investment Management L.P.'s portfolio, making the stock its 13th biggest holding. Lagoda Investment Management L.P. owned 0.22% of TransMedics Group worth $4,605,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in TMDX. Graham Capital Management L.P. increased its stake in shares of TransMedics Group by 610.0% during the fourth quarter. Graham Capital Management L.P. now owns 30,956 shares of the company's stock worth $1,930,000 after purchasing an additional 26,596 shares in the last quarter. FORA Capital LLC purchased a new stake in TransMedics Group during the 4th quarter worth approximately $1,788,000. Frontier Capital Management Co. LLC purchased a new position in shares of TransMedics Group in the fourth quarter valued at approximately $9,415,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in shares of TransMedics Group by 40.1% in the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 7,290 shares of the company's stock worth $455,000 after acquiring an additional 2,086 shares during the last quarter. Finally, Divisadero Street Capital Management LP increased its position in shares of TransMedics Group by 312.8% during the fourth quarter. Divisadero Street Capital Management LP now owns 158,480 shares of the company's stock worth $9,881,000 after purchasing an additional 120,090 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on TMDX. Oppenheimer lifted their target price on shares of TransMedics Group from $125.00 to $130.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. Canaccord Genuity Group restated a "buy" rating and issued a $104.00 target price on shares of TransMedics Group in a report on Tuesday, March 11th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Finally, Piper Sandler reissued an "overweight" rating and issued a $125.00 price objective (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $126.70.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,000 shares of the firm's stock in a transaction dated Friday, May 9th. The stock was sold at an average price of $115.63, for a total transaction of $693,780.00. Following the completion of the transaction, the director now directly owns 732 shares in the company, valued at $84,641.16. This trade represents a 89.13% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 7.00% of the company's stock.

TransMedics Group Trading Down 0.4%

TMDX stock traded down $0.55 during mid-day trading on Thursday, hitting $121.81. 957,565 shares of the company were exchanged, compared to its average volume of 1,354,809. The business has a fifty day simple moving average of $81.79 and a 200-day simple moving average of $75.70. The firm has a market capitalization of $4.12 billion, a P/E ratio of 129.59 and a beta of 1.91. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.41. The firm had revenue of $143.54 million during the quarter, compared to the consensus estimate of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.35 EPS. On average, equities research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.